An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-3102 in Patients With Impaired Hepatic Function
Latest Information Update: 11 May 2022
At a glance
- Drugs Omarigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 27 Aug 2019 Results assessing population pharmacokinetic and pharmacodynamic model by using data from phase I, II and III studies including this study published in the British Journal of Clinical Pharmacology.
- 14 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.